A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer

C. Gambacorti-Passerini, J. A. Hank, M. R. Albertini, A. A. Borchert, K. H. Moore, J. H. Schiller, R. Bechhofer, E. C. Borden, B. Storer, P. M. Sondel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nine patients with metastatic renal cell carcinoma were entered into a pilot protocol including a 4-week regimen utilizing human recombinant interleukin-2 (IL-2) and in vitro lymphokine-activated killer (LAK) cells. The regimen included 2 weeks (4 days of treatment and 3 days of rest/week) of continuous-infusion (c.i.) IL-2 at 3 x 106 U/m2/day, followed by two leukaphereses. LAK cells were cultured in vitro for 48 to 72 h and administered as a single infusion, followed by 9 days of bolus i.v. injections of 106 U IL-2/m2/dose, given every 8 hours (t.i.d.). The average (±SD) number of LAK cells infused per patient was 7.2 x 1010 (±3.5 x 1010). One patient showed >50% shrinkage of tumor (lung + renal bed recurrence). Toxicity was similar to that encountered in other studies using similar IL-2 doses and LAK cells and consisted of fever, hypotension, fluid retention, and reversible renal insufficiency. These results indicate that the 2 weeks of IL-2 c.i. provided conditions enabling the harvest of large quantities of mononuclear cells from the peripheral blood of patients; this could be useful for future trials requiring the use of in vitro activated lymphocytes. Nevertheless, these pilot data suggest that this regimen of prolonged t.i.d. IL-2 administration after the LAK infusion does not seem to generate any improvement in antitumor effects from those obtained using other LAK + IL-2 regimens.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Immunotherapy
Volume13
Issue number1
StatePublished - 1993

Fingerprint

Lymphokine-Activated Killer Cells
Kidney Neoplasms
Cell- and Tissue-Based Therapy
Interleukin-2
Lymphokines
Leukapheresis
Renal Cell Carcinoma
Hypotension
Renal Insufficiency
Blood Cells
Fever
Lymphocytes
Kidney
Recurrence
Lung
Injections

Keywords

  • Continuous infusion
  • Immunotherapy
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Renal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Gambacorti-Passerini, C., Hank, J. A., Albertini, M. R., Borchert, A. A., Moore, K. H., Schiller, J. H., ... Sondel, P. M. (1993). A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. Journal of Immunotherapy, 13(1), 43-48.

A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. / Gambacorti-Passerini, C.; Hank, J. A.; Albertini, M. R.; Borchert, A. A.; Moore, K. H.; Schiller, J. H.; Bechhofer, R.; Borden, E. C.; Storer, B.; Sondel, P. M.

In: Journal of Immunotherapy, Vol. 13, No. 1, 1993, p. 43-48.

Research output: Contribution to journalArticle

Gambacorti-Passerini, C, Hank, JA, Albertini, MR, Borchert, AA, Moore, KH, Schiller, JH, Bechhofer, R, Borden, EC, Storer, B & Sondel, PM 1993, 'A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer', Journal of Immunotherapy, vol. 13, no. 1, pp. 43-48.
Gambacorti-Passerini, C. ; Hank, J. A. ; Albertini, M. R. ; Borchert, A. A. ; Moore, K. H. ; Schiller, J. H. ; Bechhofer, R. ; Borden, E. C. ; Storer, B. ; Sondel, P. M. / A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. In: Journal of Immunotherapy. 1993 ; Vol. 13, No. 1. pp. 43-48.
@article{3be243ce8a5146ac84570c08bb42702f,
title = "A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer",
abstract = "Nine patients with metastatic renal cell carcinoma were entered into a pilot protocol including a 4-week regimen utilizing human recombinant interleukin-2 (IL-2) and in vitro lymphokine-activated killer (LAK) cells. The regimen included 2 weeks (4 days of treatment and 3 days of rest/week) of continuous-infusion (c.i.) IL-2 at 3 x 106 U/m2/day, followed by two leukaphereses. LAK cells were cultured in vitro for 48 to 72 h and administered as a single infusion, followed by 9 days of bolus i.v. injections of 106 U IL-2/m2/dose, given every 8 hours (t.i.d.). The average (±SD) number of LAK cells infused per patient was 7.2 x 1010 (±3.5 x 1010). One patient showed >50{\%} shrinkage of tumor (lung + renal bed recurrence). Toxicity was similar to that encountered in other studies using similar IL-2 doses and LAK cells and consisted of fever, hypotension, fluid retention, and reversible renal insufficiency. These results indicate that the 2 weeks of IL-2 c.i. provided conditions enabling the harvest of large quantities of mononuclear cells from the peripheral blood of patients; this could be useful for future trials requiring the use of in vitro activated lymphocytes. Nevertheless, these pilot data suggest that this regimen of prolonged t.i.d. IL-2 administration after the LAK infusion does not seem to generate any improvement in antitumor effects from those obtained using other LAK + IL-2 regimens.",
keywords = "Continuous infusion, Immunotherapy, Interleukin-2, Lymphokine-activated killer cells, Renal cancer",
author = "C. Gambacorti-Passerini and Hank, {J. A.} and Albertini, {M. R.} and Borchert, {A. A.} and Moore, {K. H.} and Schiller, {J. H.} and R. Bechhofer and Borden, {E. C.} and B. Storer and Sondel, {P. M.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "43--48",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer

AU - Gambacorti-Passerini, C.

AU - Hank, J. A.

AU - Albertini, M. R.

AU - Borchert, A. A.

AU - Moore, K. H.

AU - Schiller, J. H.

AU - Bechhofer, R.

AU - Borden, E. C.

AU - Storer, B.

AU - Sondel, P. M.

PY - 1993

Y1 - 1993

N2 - Nine patients with metastatic renal cell carcinoma were entered into a pilot protocol including a 4-week regimen utilizing human recombinant interleukin-2 (IL-2) and in vitro lymphokine-activated killer (LAK) cells. The regimen included 2 weeks (4 days of treatment and 3 days of rest/week) of continuous-infusion (c.i.) IL-2 at 3 x 106 U/m2/day, followed by two leukaphereses. LAK cells were cultured in vitro for 48 to 72 h and administered as a single infusion, followed by 9 days of bolus i.v. injections of 106 U IL-2/m2/dose, given every 8 hours (t.i.d.). The average (±SD) number of LAK cells infused per patient was 7.2 x 1010 (±3.5 x 1010). One patient showed >50% shrinkage of tumor (lung + renal bed recurrence). Toxicity was similar to that encountered in other studies using similar IL-2 doses and LAK cells and consisted of fever, hypotension, fluid retention, and reversible renal insufficiency. These results indicate that the 2 weeks of IL-2 c.i. provided conditions enabling the harvest of large quantities of mononuclear cells from the peripheral blood of patients; this could be useful for future trials requiring the use of in vitro activated lymphocytes. Nevertheless, these pilot data suggest that this regimen of prolonged t.i.d. IL-2 administration after the LAK infusion does not seem to generate any improvement in antitumor effects from those obtained using other LAK + IL-2 regimens.

AB - Nine patients with metastatic renal cell carcinoma were entered into a pilot protocol including a 4-week regimen utilizing human recombinant interleukin-2 (IL-2) and in vitro lymphokine-activated killer (LAK) cells. The regimen included 2 weeks (4 days of treatment and 3 days of rest/week) of continuous-infusion (c.i.) IL-2 at 3 x 106 U/m2/day, followed by two leukaphereses. LAK cells were cultured in vitro for 48 to 72 h and administered as a single infusion, followed by 9 days of bolus i.v. injections of 106 U IL-2/m2/dose, given every 8 hours (t.i.d.). The average (±SD) number of LAK cells infused per patient was 7.2 x 1010 (±3.5 x 1010). One patient showed >50% shrinkage of tumor (lung + renal bed recurrence). Toxicity was similar to that encountered in other studies using similar IL-2 doses and LAK cells and consisted of fever, hypotension, fluid retention, and reversible renal insufficiency. These results indicate that the 2 weeks of IL-2 c.i. provided conditions enabling the harvest of large quantities of mononuclear cells from the peripheral blood of patients; this could be useful for future trials requiring the use of in vitro activated lymphocytes. Nevertheless, these pilot data suggest that this regimen of prolonged t.i.d. IL-2 administration after the LAK infusion does not seem to generate any improvement in antitumor effects from those obtained using other LAK + IL-2 regimens.

KW - Continuous infusion

KW - Immunotherapy

KW - Interleukin-2

KW - Lymphokine-activated killer cells

KW - Renal cancer

UR - http://www.scopus.com/inward/record.url?scp=0027400195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027400195&partnerID=8YFLogxK

M3 - Article

C2 - 8435431

AN - SCOPUS:0027400195

VL - 13

SP - 43

EP - 48

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -